These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37347904)

  • 21. Outcomes in Patients with Classic Hodgkin Lymphoma Treated with ABVD: A Single-center Retrospective Study.
    Makiyama J; Imaizumi Y; Watanabe H; Fujioka M; Chiwata M; Kitanosono H; Nakashima J; Miyazaki Y; Yoshida S
    Intern Med; 2021 Mar; 60(5):709-718. PubMed ID: 33087662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: a 10-year study from China.
    Wen Q; Ge J; Lei Y; Zhang Y; Kong X; Wang W; Hou H; Wang Z; Qian S; Ding M; Dong M; Zhu L; Zhang M; Zhang X; Chen Q
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3989-4003. PubMed ID: 36030432
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma.
    Hu M; Ding Y; Zhang H; Guo W; Li Y; Jin Z; Qu C; Xia F
    Front Pharmacol; 2023; 14():1195907. PubMed ID: 37680722
    [No Abstract]   [Full Text] [Related]  

  • 24. ABVD or BEACOPP
    Fermé C; Thomas J; Brice P; Casasnovas O; Vranovsky A; Bologna S; Lugtenburg PJ; Bouabdallah R; Carde P; Sebban C; Eghbali H; Salles G; van Imhoff GW; Thyss A; Noordijk EM; Reman O; Lybeert MLM; Janvier M; Spina M; Audhuy B; Raemaekers JMM; Delarue R; Anglaret B; de Weerdt O; Marjanovic Z; Tersteeg RJHA; de Jong D; Brière J; Henry-Amar M; ;
    Eur J Cancer; 2017 Aug; 81():45-55. PubMed ID: 28601705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
    Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
    J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Wells WA; Winter JN; Horning SJ; Dar AR; Shustik C; Stewart DA; Crump M; Djurfeldt MS; Chen BE; Shepherd LE; ;
    N Engl J Med; 2012 Feb; 366(5):399-408. PubMed ID: 22149921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hodgkin lymphoma in Chile: experience of the national adult cancer program].
    Cabrera ME; García H; Lois V; León A; Peña K; Rossle A; Cerda B; Rojas H; Meneses P; Merino C; Aspillaga A; Vittini de C; Oliva J; Hales C; Rosas J;
    Rev Med Chil; 2007 Mar; 135(3):341-50. PubMed ID: 17505580
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496).
    Gordon LI; Hong F; Fisher RI; Bartlett NL; Connors JM; Gascoyne RD; Wagner H; Stiff PJ; Cheson BD; Gospodarowicz M; Advani R; Kahl BS; Friedberg JW; Blum KA; Habermann TM; Tuscano JM; Hoppe RT; Horning SJ
    J Clin Oncol; 2013 Feb; 31(6):684-91. PubMed ID: 23182987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States.
    Winter A; Liu N; Surinach A; Fanale M; Yu KS; Narkhede M
    Clin Lymphoma Myeloma Leuk; 2023 Jul; 23(7):527-534. PubMed ID: 37121857
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome.
    Savage KJ; Skinnider B; Al-Mansour M; Sehn LH; Gascoyne RD; Connors JM
    Blood; 2011 Oct; 118(17):4585-90. PubMed ID: 21873543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.
    Bhethanabhotla S; Jain S; Kapoor G; Mahajan A; Chopra A; Vishnubhatla S; Bakhshi S
    Leuk Lymphoma; 2017 Jul; 58(7):1617-1623. PubMed ID: 27919174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
    Santoro A; Mazza R; Spina M; Califano C; Specchia G; Carella M; Consoli U; Palombi F; Musso M; Pulsoni A; Kovalchuk S; Bonfichi M; Ricci F; Fabbri A; Liberati AM; Rodari M; Giordano L; Chimienti E; Balzarotti M; Sorasio R; Gallamini A; Ghiggi C; Ciammella P; Ricardi U; Chauvie S; Carlo-Stella C; Merli F
    Ann Hematol; 2021 Oct; 100(10):2547-2556. PubMed ID: 34327561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
    Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
    Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ABVD-Based Therapy for Hodgkin Lymphoma in Children and Adolescents: Lessons Learnt in a Tertiary Care Oncology Center in a Developing Country.
    Jain S; Kapoor G; Bajpai R
    Pediatr Blood Cancer; 2016 Jun; 63(6):1024-30. PubMed ID: 26855007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group.
    Diehl V; Pfreundschuh M; Löffler M; Rühl U; Hiller E; Gerhartz H; Wilmanns W; Kirchner H; Schoppe W; Petsch S
    Med Oncol Tumor Pharmacother; 1989; 6(2):155-62. PubMed ID: 2473363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.
    Jalali A; Ha FJ; Chong G; Grigg A; Mckendrick J; Schwarer AP; Doig R; Hamid A; Hawkes EA
    Ann Hematol; 2016 Apr; 95(5):809-16. PubMed ID: 26878861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study.
    Mponda M; Kudowa E; Craven DM; Eastburg LC; Chikasema M; Kasonkanji E; Tomoka T; Roush SM; Simwinga L; Mumba N; Gopal S; Fedoriw Y; Painschab MS
    EClinicalMedicine; 2024 Mar; 69():102480. PubMed ID: 38356728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary.
    McLaughlin M; Kelsey TW; Wallace WH; Anderson RA; Telfer EE
    Hum Reprod; 2017 Jan; 32(1):165-174. PubMed ID: 27923859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
    Vijenthira A; Chan K; Cheung MC; Prica A
    Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcome of patients with early stage favorable Hodgkin lymphoma treated with ABVD × two cycles followed by FDG-PET/CT restaging and 20 Gy of involved-site radiotherapy.
    Kamran SC; Jacene HA; Chen YH; Mauch PM; Ng AK
    Leuk Lymphoma; 2018 Jun; 59(6):1384-1390. PubMed ID: 28937297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.